Cure Duchenne

“Debra and paul miller have a family relationship.”

“Form 990 will be available to the board to review prior to filing at the regularly schedule board meetings. However, a limited number of board members will review the entire form 990 prior to filing.”

“The board of directors are required to review and sign the conflict of interest policy at least annually. The board member must inform the rest of the board if a conflict arises or if it exists.”

“Compensation of top management and officers of the organization are reviewed by independent legal counsel and submitted to the board members for approval.”

“The organziation's audited financial statements and form 990 are available to the public upon request.”

“Cure duchenne made two separate investments in prosensa holdings, n.v., a privately held company located in the netherlands. In november 2004, cure duchenne invested $336,250. In december 2006, a portion of a non-interest bearing loan in the amount of $485,425 was converted to equity common shares. See balance sheet and footnote no. 1. The funds contributed by cure duchenne are restricted for research to finding a cure for duchenne muscular dystrophy. The organization monitors prosensa's research activities to ensure proper utilization of the contributed funds. The equity interest may provide the organization with addtional capital in the future to fund other research projects for duchenne muscular dystrophy. In 2013, prosena holding, n.v. Became a publicily traded company listed on the nasdaq. As such, the value reflected on the balance sheet at december 31, 2013 is carried at market value. During 2014, prosena holdings, n.v. Was purchased by biomarin pharmacueticals, inc. Biomarin has decided to de-list prosena holding, n.v. From the nasdaq and will be purchasing back all of prosena holding, n.v's outstanding stock. The value reflected on the balance sheet at december 31, 2014 is carried at cost of $17.75 per share, which is the agreed upon price between biomarin pharmaceutical and prosena holding, n.v. For prosena's outstanding stock.”

“The organization made two separate investments in prosensa holdings, n.v., a privately held company located in the netherlands. In november 2004, cure duchenne invested $336,250. In december 2006, a portion of a non-interest bearing loan in the amount of $485,425 was converted to equity common shares. These contributed funds are restricted for use in research directly related to finding a cure for duchenne muscular dystrophy. Cure duchenne's board monitors prosensa's research activities and authorizes release of additional funds to prosensa for further research as objectives are met by prosensa. Cure duchenne received a equity interest in prosensa for the contributions. The equity interest enables cure duchenne to monitor prosensa's research efforts to finding a cure for duchenne muscular dystrophy. Additionally, the equity interest in prosensa may provide cure duchenne with additional capital in the future to fund other research projects for duchenne muscular dystrophy. In 2013, prosena holding, n.v. Became a publicily traded company listed on the nasdaq. As such, the value reflected on the balance sheet at december 31, 2013 is carried at market value. During 2014, prosena holdings, n.v. Was purchased by biomarin pharmacueticals, inc. Biomarin has decided to de-list prosena holding, n.v. From the nasdaq and will be purchasing back all of prosena holding, n.v's outstanding stock. The value reflected on the balance sheet at december 31, 2014 is carried at cost of $17.75 per share, which is the agreed upon price between biomarin pharmaceutical and prosena holding, n.v. For prosena holding's outstanding stock.”